Scott E. Hadland, MD, MPH,1,2 John R. Knight, MD,1,3 and Sion K. Harris, PhD1,2,3
Author information ► Copyright and License information ►
The publisher's final edited version of this article is available at J Dev Behav Pediatr
See other articles in PMC that cite the published article.
Abstract
Marijuana policy is rapidly evolving in the United States and elsewhere, with cannabis sales fully legalized and regulated in some jurisdictions and use of the drug for medicinal purposes permitted in many others. Amidst this political change, patients and families are increasingly asking whether cannabis and its derivatives may have therapeutic utility for a number of conditions, including developmental and behavioral disorders in children and adolescents. This review examines the epidemiology of cannabis use among children and adolescents, including those with developmental and behavioral diagnoses. It then outlines the increasingly well-recognized neurocognitive changes shown to occur in adolescents who use cannabis regularly, highlighting the unique susceptibility of the developing adolescent brain and describing the role of the endocannabinoid system in normal neurodevelopment. The review then discusses some of the proposed uses of cannabis in developmental and behavioral conditions, including attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Throughout, the review outlines gaps in current knowledge and highlights directions for future research, especially in light of a dearth of studies specifically examining neurocognitive and psychiatric outcomes among children and adolescents with developmental and behavioral concerns exposed to cannabis
Conclusion
Given the current scarcity of data, cannabis cannot be safely recommended for the treatment of developmental or behavioral disorders at this time. At best, some might consider its use as a last-line therapy when all other conventional therapies have failed.92,93 As marijuana policy evolves and as the drug becomes more readily available, it is important that practicing clinicians recognize the long-term health and neuropsychiatric consequences of regular use. Although a decades-long public health campaign has showcased the harms of cigarette smoking, similar movements to illustrate the hazards of cannabis use have not been as rigorous or successful. As a result, accurate information on regular cannabis use remains poorly disseminated to patients, families and physicians. Further, there are especially few studies examining neurocognitive and psychiatric outcomes among children and adolescents with developmental or behavioral concerns who are exposed to cannabis, and this remains a critical area for future study. In coming to the decision to use marijuana for medicinal purposes, all parties should be fully aware of the long-term hazards of regular cannabis use, recognize the lack of evidence on its efficacy in developmental and behavioral conditions, and incorporate this information into a careful risk-benefit analysis.
For complete paper (cited 5/4/16)
Featured Website
World Federation Against Drugs
World Federation Against Drugs (W.F.A.D) Dalgarno Institute is a member of this global initiative. For evidence based data on best practice drug policy in the global context.
Featured Website
Institute for Behavior and Health
The Institute for Behavior and Health, Inc. is to reduce the use of illegal drugs. We work to achieve this mission by conducting research, promoting ideas that are affordable and scalable...
Featured Website
Drug Free Australia
Drug Free Australia Website. Drug Free Australia is a peak body, representing organizations and individuals who value the health and wellbeing of our nation...
Featured Website
Drug Advisory Council of Australia (D.A.C.A)
Drug Advisory Council of Australia (D.A.C.A) Dalgarno Institute is an executive member of this peak body. For updates on current illicit drug issues.
Featured Website
International Task Force on Strategic Drug Policy
(I.T.F.S.D.P) This international peak body continues to monitor and influence illicit drug policy on the international stage. Dalgarno Institute is a member organisation.
Featured Website
Smart Approaches to Marijuana
Smart Approaches to Marijuana. SAM's leaders are among the world's most prominent voices calling for science-based marijuana education and awareness.
21 Be There
There isn’t merely data sharing - it isn't about promoting a 'one dimensional' legislative solution to a complex problem
Featured Website
Drug Free Futures
Drug Policy Futures believes in engaging in an open dialogue about the strengths and weaknesses of global drug policies...
Featured Website
Action Alcohol
The National Alliance for Action on Alcohol is a national coalition of health and community organisations from across Australia that has been formed with the goal of reducing alcohol-related harm.
Featured Website
Rivermend Health
RiverMend Health is a premier provider of scientifically driven, specialty behavioral health services to those suffering from alcohol and drug dependency, dual disorders, eating disorders, obesity and chronic pain.
Featured Website
Evidence-Based Practices Resource Center
SAMHSA is committed to improving prevention, treatment, and recovery support services for mental and substance use disorders.
Featured Website
SAMHSA
SAMHSA is committed to improving prevention, treatment, and recovery support services for mental and substance use disorders.